Join AARP
Get exclusive member benefits & effect social change. Join Today
Symptomatic treatment of seasonal or perennial rhinitis when conventional therapy with antihistamines or decongestants is ineffective or is not tolerated.
Generally provides symptomatic relief of watery rhinorrhea, nasal congestion, sneezing, postnasal drip, and nasal itching; generally does not relieve signs and symptoms of conjunctivitis, although improvement in ophthalmic manifestations may occur.
Relieves symptoms in both allergic and nonallergic rhinitis, although experience is more extensive with allergic rhinitis.
Has been used successfully prior to the onset of the pollen season for the prophylaxis of symptoms of seasonal allergic rhinitis†.
Administer by nasal inhalation using a metered-dose nasal spray pump.
Avoid contact with the eyes.
If used once daily, administer preferably in the morning. Generally, initiate therapy with once-daily dosing; some patients may obtain greater relief with twice-daily divided dosing.
Although regular dosing generally provides optimal benefit, as needed (prn) dosing may be adequate in some patients with seasonal allergic rhinitis.
Clear nasal passages prior to administration. If nasal passages are blocked, a topical nasal decongestant can be administered 5–15 minutes before intranasal administration.
Prime pump prior to initial use or after a period of nonuse (i.e., ≥1 week).
Tilt the head slightly forward, insert the nasal adapter into one nostril, and point the tip of the adapter toward the inflamed nasal turbinates and away from the nasal septum.
Pump the drug into one nostril while holding the other nostril closed and concurrently inspire through the nose. Repeat procedure for the other nostril.
After removing the nasal adapter and dust cap, these pieces should be rinsed in warm water and dried thoroughly; do not clean by inserting a sharp object into the piece.
Nasal inhaler delivers about 50 mcg of fluticasone propionate per metered spray and about 120 metered sprays per 16-g container.
Adjust dosage according to individual requirements and response.
Therapeutic effects of intranasal corticosteroids, unlike those of decongestants, are not immediate. This should be explained to the patient in advance to ensure compliance and continuation of the prescribed treatment regimen.
Generally assess response to the initial dosage 4–7 days after starting therapy; a reduction in maintenance dosage may be possible at that time.
Adolescents and children ≥4 years of age: 1 spray (50 mcg) in each nostril once daily (total dose: 100 mcg/day). Increase dosage to 2 sprays (100 mcg) in each nostril daily (total dose: 200 mcg/day) if response is inadequate.
Reduce dosage to 1 spray in each nostril (total dose: 100 mcg/day) once adequate symptom control is achieved.
Some patients ≥12 years of age with seasonal allergic rhinitis may find as needed (prn) use of 200 mcg (100 mcg in each nostril) doses (no more frequently than once daily) to be effective in controlling symptoms. Greater symptom control may be achieved with regular dosing.
Adolescents and children ≥4 years of age: 1 spray (50 mcg) in each nostril daily (total dose: 100 mcg/day). Increase dosage to 2 sprays (100 mcg) in each nostril daily (total dose: 200 mcg/day) if response is inadequate.
Maintenance dose is 1 spray in each nostril (total dose: 100 mcg/day) once adequate symptom control is achieved.
Usual initial dose is 2 sprays (100 mcg) in each nostril once daily (total 200 mcg/day). Alternatively, 1 spray (50 mcg) in each nostril twice daily (total 200 mcg/day).
Maintenance dose is 1 spray in each nostril (total dose: 100 mcg/day) once adequate symptom control is achieved.
Some patients with seasonal allergic rhinitis may find as needed (prn) use of 200-mcg (100 mcg in each nostril) doses (no more frequently than once daily) to be effective in controlling symptoms. Greater symptom control may be achieved with regular dosing.
Maintenance dose is 2 sprays (100 mcg) in each nostril daily (200 mcg total).†
Usual initial dose is 2 sprays (100 mcg) in each nostril once daily (total dose: 200 mcg/day). Alternatively, 1 spray (50 mcg) in each nostril twice daily (total 200 mcg/day).
Maintenance dose is 1 spray in each nostril (total dose: 100 mcg/day) once adequate symptom control is achieved.
No evidence that higher than recommended dosages or increased frequency of administration is beneficial.
Exceeding the maximum recommended daily dosage may only increase the risk of adverse systemic effects (e.g., HPA-axis suppression, Cushing’s syndrome).
Adolescents and children ≥4 years of age: Maximum 100 mcg (2 sprays) in each nostril (200 mcg total) daily.
Adolescents and children ≥4 years of age: Maximum 100 mcg (2 sprays) in each nostril (200 mcg total) daily.
Maximum 100 mcg (2 sprays) in each nostril (200 mcg total) daily.
Maximum 100 mcg (2 sprays) in each nostril (200 mcg total) daily.
No specific dosage recommendations for hepatic impairment.
No specific dosage recommendations for renal impairment.
No specific geriatric dosage recommendations.
|
Enter your symptoms in our Symptom Checker to find out possible causes of your symptoms. Go.
|
|
Enter any list of prescription drugs and see how they interact with each other and with other substances. Go.
|
|
Enter its color and shape information, and this tool helps you identify it. Go.
|
Member access to caregiving support services with AARP® Caregiving Help and Advice from Genworth.
Members save 20% off on personal training and group fitness with American Council on Exercise.
Members save on hearing care with the AARP® Hearing Care Program provided by HearUSA.
Members receive exclusive member benefits and affect social change. Join Today
Get tips, recipes and advice for reaching your personal weight loss goal! Join
Share health coverage information and experiences common to being age 50+. Join
Share heart-smart recipes, fitness tips and stress relievers. Join